Loading...
•
Dec 31, 2024
Integra LifeSciences Q4 2024 Earnings Report
Reported an increase in revenue and adjusted EPS compared to the fourth quarter of 2023.
Key Takeaways
Integra LifeSciences reported a revenue of $442.6 million for Q4 2024, an 11.5% increase compared to Q4 2023. GAAP earnings per diluted share were $0.25, while adjusted earnings per diluted share were $0.97.
Reported revenues increased by 11.5% on a reported basis and 3.5% on an organic basis compared to Q4 2023.
GAAP earnings per diluted share were $0.25, the same as in Q4 2023.
Adjusted earnings per diluted share were $0.97, compared to $0.89 in Q4 2023.
Codman Specialty Surgical revenues increased by 15.8%, while Tissue Technologies revenues increased by 2.1%.
Revenue by Segment
Forward Guidance
For the full-year 2025, the Company expects revenues to be in the range of $1,650 million to $1,715 million, representing reported growth of 2.4% to 6.5% and organic growth of 1.0% to 5.0%. Adjusted earnings per diluted share are expected to be between $2.41 and $2.51.
Positive Outlook
- Strong demand for the Company’s portfolio
- Full year of the Acclarent acquisition
- Revenue growth of 2.4% to 6.5%
- Organic growth of 1.0% to 5.0%
- Adjusted earnings per diluted share between $2.41 and $2.51
Challenges Ahead
- Potential for intermittent ship holds as the company continues to implement its Compliance Master Plan
- Strength of the U.S. dollar
- Temporary production delays on Integra Skin
- Organic growth of -6.2% to -3.5% (Q1 2025)
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...